Praevomed GmbH was founded in 1996 and represents the fusion of scientific
research at academic institutions and many years of experience and expertise
in drug marketing and medicine.
As research based company Praevomed is operating in the field of preventive
medicine with the aim of improving quality of life.
Besides the development of 2 products, distributed as food supplements
in the indications cancer and diabetes, 3 dermato-cosmetics for skin damages
due to therapeutic radiation (cancer) and microcirculation disturbances
(diabetes), Praevomed is the owner of a worldwide patented substance,
similar to BRM's, in the field of oncology in the current development
As Praevomed has committed its capital to the research of chemopreventive
agents and new innovative dermato-cosmetic products it therefore has not
established own sales and marketing structures.
Consequently Praevomed cooperates with experienced partners in the German
market who are distributing Praevomed`s own developments. Beyond this
Praevomed is looking for suitable distribution partners worldwide.
For more information please contact Dr. med. H. Stolze, CEO, Nonnenstieg
86 , 37075 Goettingen, Germany, Phone: +49 551 2709; Telefax: +49 551
Praevomed is seeking a corporate partner with a committment to cancer
therapeutics to collaborate in the funding of further clinical development
in exchange for marketing rights for a worldwide patented substance.
It offers a totally new approach to inhibit metastasis formation simply
by inhibition of migration, furthermore the substance causes a reversible
inhibition of ras-and myc-induced neoplastic properties in transformed
fibroblasts by selective down-regulation of retroviral RNA levels.
The substance is introducible into oncology for 1. prevention ( metastasis
formation after RO / R1-removal of the primary) and 2. an active substance
against some tumor entities, currently demonstrated for renal cell carcinoma,
melanoma, prostate cancer and carcinoids.
The substance is an exciting compound which can become the cornerstone
in all oncology treatment regimes and has an upside potential in utilizing
as chronic treatment through its effectiveness and very low toxicity profile.
By generating the expected efficacy data this product will become a major
takeover target for pharmaceutical and Biotech companies who need to enhance
their oncology portfolios.